Alexopoulos G. S. (2005). Depression in the elderly. Lancet, 365, 1961–1970.
Almeida O. P., Alfonso H., Jamrozik K., Hankey G. J. and Flicker L. (2010). Aspirin use, depression, and cognitive impairment in later life: the health in men study. Journal of the American Geriatrics Society, 58, 990–992.
Ancill R. J. and Holliday S. G. (1990). Treatment of depression in the elderly: a Canadian view. Prog Neuropsychopharmacol Biol Psychiatry, 14, 655–661.
ASPREE Investigator Group (2013). Study design of ASPirin in reducing events in the elderly (ASPREE): a randomized, controlled trial. Contemporary Clinical Trials, 36, 555–564.
et al. (2013). Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Medicine, 11, 74.
et al. (2006). Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. International Clinical Psychopharmacology, 21, 219–225.
Chen Y. G.
et al. (2006). Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chinese Medical Journal (Engl), 119, 32–36.
Cuijpers P., van Straten A., Smit F., Mihalopoulos C. and Beekman A. (2008). Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions. American Journal of Psychiatry, 165, 1272–1280.
Dean B., Tawadros N., Scarr E. and Gibbons A. S. (2010). Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. Journal of Affective Disorders, 120, 245–248.
Dozeman E., van Schaik D. J., van Marwijk H. W., Stek M. L., van der Horst H. E. and Beekman A. T. (2011). The center for epidemiological studies depression scale (CES-D) is an adequate screening instrument for depressive and anxiety disorders in a very old population living in residential homes. International Journal of Geriatric Psychiatry, 26, 239–246.
Fisher M., Cushman M., Knappertz V. and Howard G. (2008). An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration. American Heart Journal, 156, 106–111.
Gao X. R.
et al. (2009). Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome. Journal of Pharmacy and Pharmacology, 61, 1505–1510.
Ghubash R., Daradkeh T. K., Al Naseri K. S., Al Bloushi N. B. and Al Daheri A. M. (2000). The performance of the center for epidemiologic study depression scale (CES-D) in an Arab female community. International Journal of Social Psychiatry, 46, 241–249.
Hiles S. A., Baker A. L., de Malmanche T. and Attia J. (2012). A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behavior and Immunity, 26, 1180–1188.
Ikonomidis I., Andreotti F., Economou E., Stefanadis C., Toutouzas P. and Nihoyannopoulos P. (1999). Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation, 100, 793–798.
Jenny N. S.
et al. (2012). Long-term assessment of inflammation and healthy aging in late life: the cardiovascular health study all stars. The Journals of Gerontology, Series A Biological Sciences and Medical Sciences, 67, 970–976.
Krishnadas R. and Cavanagh J. (2012). Depression: an inflammatory illness?
Journal of Neurology, Neurosurgery & Psychiatry, 83, 495–502.
Liu Y., Ho R. C. and Mak A. (2012). Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. Journal of Affective Disorders, 139, 230–239.
et al. (2012a). Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Medicine, 10, 66.
Maes M., Fisar Z., Medina M., Scapagnini G., Nowak G. and Berk M. (2012b). New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates–Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology, 20, 127–150.
Mendlewicz J., Kriwin P., Oswald P., Souery D., Alboni S. and Brunello N. (2006). Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. International Clinical Psychopharmacology, 21, 227–231.
Moylan S., Maes M., Wray N. R. and Berk M. (2013). The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Molecular Psychiatry, 18, 595–606.
et al. (2015) A shared framework for the common mental disorders and non-communicable disease: key considerations for disease prevention and control. BMC Psychiatry. 5, 15.
Palsson S. P., Ostling S. and Skoog I. (2001). The incidence of first-onset depression in a population followed from the age of 70 to 85. Psychological Medicine, 31, 1159–1168.
Pasco J. A.
et al. (2010a). Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychotherapy and Psychosomatics, 79, 323–325.
Pasco J. A.
et al. (2010b). Association of high-sensitivity C-reactive protein with de novo major depression. British Journal of Psychiatry, 197, 372–377.
Tuunainen A., Langer R. D., Klauber M. R. and Kripke D. F. (2001). Short version of the CES-D (Burnam screen) for depression in reference to the structured psychiatric interview. Psychiatry Research, 103, 261–270.
Wang Y., Yang F., Liu Y. F., Gao F. and Jiang W. (2011). Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. Neuroscience Letters, 499, 74–79.